Bio-Techne (TECH) rose 4% on a report that activist investor Ananym Capital Management has accumulated a stake in the maker of life-sciences tools and wants the company to pursue a strategic review, ...

In the latest quarter, 7 analysts provided ratings for Bio-Techne (NASDAQ:TECH), showcasing a mix of bullish and bearish perspectives. The table below provides a snapshot of their recent ratings, ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Merck KGaA, Darmstadt, Germany, and Bio-Techne announced they entered into a definitive agreement under which Merck KGaA will acquire Bio-Techne for $73 per share in cash. The transaction represents a ...

Bio-Techne faces near-term growth headwinds from challenges in academic and biotech research funding, but retains strong leverage to growing spatial biology, proteomics, and cell/gene therapy research ...

The life sciences tools and services sector is back in focus after Merck KGaA (MKGAF) agreed to acquire Bio-Techne (TECH) for $73 per share in cash, valuing the deal at an enterprise value of around ...

Develops and manufactures life science reagents, analytical instruments, and diagnostic products, including proteins, antibodies, assays, and molecular diagnostic kits Generates revenue through the ...

Bio-Techne Corporation today announced that Advanced Cell Diagnostics (ACD), part of Bio-Techne's Spatial Biology Division, has surpassed 10,000 peer-reviewed publications referencing the use and ...

Activist Ananym builds stake in Bio-Techne (NASDAQ: TECH), urges ... This is a premium only article. To continue reading this and other premium stock market news ...

Gemini Bioproducts announced the acquisition of selected fetal bovine serum product rights and inventory from Bio-Techne (TECH). GeminiBio has a 39-year history of supporting FBS customers. With this ...

June 25 (Reuters) - German ⁠drugmaker ⁠Merck KGaA said on Thursday it would ⁠buy U.S. firm Bio-Techne for $11.3 billion, its biggest deal in more than a decade, betting on demand for complex drug ...